Moderna (MRNA) PT Raised to $32 at Piper Jaffray After Positive Ph1 Data
Tweet Send to a Friend
Piper Jaffray analyst Edward Tenthoff raised the price target on Moderna (NASDAQ: MRNA) to $32.00 (from $30.00) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
